17:01 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest combining CD40 agonists and CSF1R inhibitors could help treat colorectal cancer. In two mouse models of colon cancer, an anti-CD40 agonist antibody plus an anti-CSF1R antibody inhibitor decreased tumor...
21:30 , Sep 29, 2017 |  BC Week In Review  |  Company News

Cancer Research, Parker Institute partner to test I-O combos for pancreatic cancer

CRI and the Parker Institute for Cancer Immunotherapy partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Apexigen Inc. (San Carlos, Calif.) to evaluate combinations of immunotherapies with chemotherapy to treat pancreatic cancer. The partners started a...
11:02 , Sep 20, 2017 |  BC Extra  |  Company News

Cancer Research, Parker Institutes to test I-O combos for pancreatic cancer

Cancer Research Institute (CRI) and the Parker Institute for Cancer Immunotherapy partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Apexigen Inc. (San Carlos, Calif.) to evaluate combinations of immunotherapies with chemotherapy to treat pancreatic cancer. The...
10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
23:14 , Apr 13, 2017 |  BC Week In Review  |  Company News

Bristol-Myers Squibb, Apexigen deal

Apexigen will conduct a Phase I/II trial combining its APX005M with PD-1 inhibitor Opdivo nivolumab from Bristol-Myers. The trial will enroll second-line patients with metastatic non-small cell lung cancer (NSCLC) or metastatic melanoma. The companies...
20:53 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

APX005M: Ph I/II started

Apexigen began an open-label, U.S. Phase I/II trial to evaluate intratumoral APX005M given every 3 weeks for up to 4 doses plus IV Keytruda pembrolizumab in about 41 patients. The Phase I portion will evaluate...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

APX005M: Phase I started

Apexigen began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV APX005M every 3 weeks in about 32 patients. Apexigen Inc., San Carlos, Calif.   Product: APX005M   Business: Cancer   Molecular target: CD40   Description:...